AbbVie reports 14.7-month median survival for Temab-A combination in early-stage colorectal cancer trial

By Public Technologies
  • AbbVie will present updated solid-tumor study results at the ESMO Congress in Madrid, October 23-27, 2026.
  • Temab-A with bevacizumab showed longer median survival than standard care in previously treated colorectal cancer, supporting an ongoing Phase 3 trial.
  • In lung cancer, Temab-A showed tumor responses, including activity against brain metastases; no new safety signals emerged in the brain-metastases analysis.
  • The investigational drug recently received FDA Breakthrough Therapy designations for colorectal cancer and non-small cell lung cancer.
  • ABBV-706 showed tumor responses in previously treated small cell lung cancer, supporting continued Phase 3 evaluation against standard care.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. AbbVie Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202610181810PR_NEWS_USPR_____CG74688) on October 18, 2026, and is solely responsible for the information contained therein.

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.